Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)

International Journal of Cancer

Volumn 127, Issue 8, 2010, Pages 1813-1822

  Sotomayor, Sandra ^a   Muñoz Moreno, Laura ^a   Carmena, Marìa J ^a   Schally, Andrew V ^b   Sànchez Chapado, Manuel ^a   Prieto, Juan C ^a   Bajo, Ana M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

bombesin antagonist; cytotoxic bombesin analog; EGFR; HER 2; HER 2 transactivation; HER 3; prostate cancer

Indexed keywords

AN 215; BOMBESIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; RC 3095; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BOMBESIN; BOMBESIN (6 14), TPI(6) LEU(13) PSI(CH2NH) LEU(14); BOMBESIN (6-14), TPI(6)-LEU(13)-PSI(CH2NH)-LEU(14)-; DOXORUBICIN; DRUG DERIVATIVE; HER2 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BOMBESIN; CELL PROLIFERATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 77956996168     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25192     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Hamdy FC, Thomas BG,. New therapeutic concepts in prostate cancer. BJU Int 2001; 88 (suppl 2): 43-8.
3. Schally AV, Nagy A,. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003; 72: 2305-20.
4. Sun B, Schally AV, Halmos G,. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 2000; 90: 77-84.
5. Gonzàlez N, Moody TW, Igarashi H, Ito T, Jensen RT,. Bombesin-related peptides and their receptors. Recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 2008; 15: 58-64.
6. Smith CJ, Volkert VA, Hoffman TJ,. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nuclear Med Biol 2005; 32: 733-40.
7. Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR,. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63: 3495-502.
8. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J,. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996; 16: 297-306.
9. Reile H, Armatis PE, Schally AV,. Characterization of high affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: Internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994; 25: 29-38.
10. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M,. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989; 63: 1714-20.
11. Shimoda J,. Effects of bombesin and its antibody on growth of human prostatic carcinoma cell lines. Jpn J Urol 1992; 83: 1459-68.
12. Hoosein NM, Logothetis CJ, Chung LW,. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993; 149: 1209-13.
13. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S,. Neuroendocrine differentiation and the bombesin/gastrin releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate 1998; 8: 52-61.
14. Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV,. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its potent derivative, 2- pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1997; 94: 652-6.
15. Nagy A, Armatis P, Schally AV,. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 5001000 times more potent; structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 1996; 93: 2464-9.
16. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G,. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215. Int J Cancer 2000; 88: 652-7.
17. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M,. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64: 303-15.
18. 2 or its derivatives. Proc Natl Acad Sci USA 1994; 91: 12664-8.
19. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowsky A, Varga JL, Halmos G,. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22: 248-291.
20. Prenzel N, Fisher OM, Streit S, Hart S, Ulrich A,. The epidermal growth factor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-31.
21. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A,. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006; 1766: 120-39.
22. Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sànchez-Chapado M, Prieto JC, Bajo AM,. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: antagonistic action of an analog of growth-hormone-releasing hormone. Int J Oncol 2007; 31: 1223-30.
23. Schally AV, Nagy A,. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15: 300-10.
24. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K,. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci USA 2002; 99: 3836-41.
25. Cornelio DB, Roesler R, Schwartsmann G,. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007; 18: 1457-66.
26. Schulz S, Röcken C, Schulz S,. Immunohistochemical detection of bombesin receptor subtypes GRPR and BRS-3 in human tumors using novel antipeptide antibodies. Virchows Arch 2006; 449: 421-7.
27. Benya RV, Kusui T, Katsuno T, Tsuda T, Mantey SA, Battey JF, Jensen RT,. Glycosylation of the gastrin-releasing peptide receptor and its effect on expression, G protein coupling, and receptor modulatory processes. Mol Pharmacol 2000; 58: 1490-501.
28. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Tailor CR, Datar R, Cote RJ,. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 2006; 97: 170-8.
29. Hassan S, Dobner PR, Carraway RE,. Involvement of MAP-kinase, PI3-kinase, and EGFR receptor in the stimulatory effect of neurotensin on DNA synthesis in PC-3 cells. Regul Pept 2004; 120: 155-66.
30. Tice DA, Biscardi JS, Nickles AL, Parsons SJ,. Mechanisms of biology synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 1999; 96: 1415-20.